Sanctuary Advisors LLC Invests $3.40 Million in Illumina, Inc. $ILMN

Sanctuary Advisors LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 19,356 shares of the life sciences company’s stock, valued at approximately $3,403,000.

Several other institutional investors also recently modified their holdings of ILMN. HighPoint Advisor Group LLC grew its position in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the period. Elevation Wealth Partners LLC lifted its holdings in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares during the period. Meeder Advisory Services Inc. grew its stake in shares of Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the period. Toronto Dominion Bank increased its position in shares of Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 0.8%

NASDAQ:ILMN opened at $224.99 on Wednesday. Illumina, Inc. has a one year low of $88.00 and a one year high of $226.84. The firm has a market cap of $33.97 billion, a P/E ratio of 41.98, a P/E/G ratio of 3.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a 50-day simple moving average of $190.35 and a 200-day simple moving average of $153.78.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the business earned $1.19 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,095,958 shares of company stock valued at $401,720,974 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Citigroup upped their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Canaccord Genuity Group lifted their price objective on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Guggenheim raised their price target on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.